Symbols / ERAS Stock $21.49 -4.36% Erasca, Inc.

Healthcare • Biotechnology • United States • NMS
ERAS (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Jonathan E. Lim M.D.
Exch · Country NMS · United States
Market Cap 6.68B
Enterprise Value 6.45B
Income -124.55M
Sales —
FCF (ttm) -66.76M
Book/sh 1.14
Cash/sh 0.89
Employees 103
Insider 10d —
IPO Jul 16, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -39.68
PEG —
P/S —
P/B 18.78
P/C —
EV/EBITDA -50.27
EV/Sales —
Quick Ratio 9.77
Current Ratio 10.04
Debt/Eq 14.50
LT Debt/Eq —
EPS (ttm) -0.44
EPS next Y -0.54
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-13
Earnings (prior) 2026-03-12
ROA -18.28%
ROE -33.27%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 310.80M
Shs Float 224.17M
Insider Own 10.66%
Instit Own 76.07%
Short Float 12.26%
Short Ratio 5.66
Short Interest 33.97M
52W High 24.28
vs 52W High -11.49%
52W Low 1.06
vs 52W Low 1,927.36%
Beta 1.05
Impl. Vol. 1.93%
Rel Volume 1.09
Avg Volume 5.26M
Volume 5.74M
Target (mean) $18.10
Tgt Median $20.00
Tgt Low $2.00
Tgt High $25.00
# Analysts 10
Recom Buy
Prev Close $22.47
Price $21.49
Change -4.36%
About

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$18.10
Mean price target
2. Current target
$21.49
Latest analyst target
3. DCF / Fair value
$-3.87
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$21.49
Low
$2.00
High
$25.00
Mean
$18.10

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-18 main JP Morgan Overweight → Overweight $25
2026-03-16 main Guggenheim Buy → Buy $20
2026-03-13 main Piper Sandler Overweight → Overweight $18
2026-03-13 main Mizuho Outperform → Outperform $19
2026-03-13 main HC Wainwright & Co. Buy → Buy $20
2026-03-06 main Clear Street Buy → Buy $20
2026-01-26 main HC Wainwright & Co. Buy → Buy $15
2026-01-16 main Piper Sandler Overweight → Overweight $11
2026-01-13 main HC Wainwright & Co. Buy → Buy $11
2026-01-07 init Piper Sandler — → Overweight $5
2025-12-09 main Mizuho Outperform → Outperform $5
2025-11-14 main Guggenheim Buy → Buy $5
2025-10-16 init Stifel — → Buy $4
2025-09-03 down B of A Securities Buy → Underperform $1
2025-08-18 down Morgan Stanley Overweight → Equal-Weight $2
2025-04-30 reit HC Wainwright & Co. Buy → Buy $6
2025-03-26 init Raymond James — → Outperform $5
2025-03-21 main Goldman Sachs Buy → Buy $3
2025-03-21 reit HC Wainwright & Co. Buy → Buy $6
2025-01-07 up B of A Securities Neutral → Buy $5
News
RSS: Latest ERAS news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-04 MORRIS SHANNON R. M.D., PH.D. Officer — 20,000 $15.04 $300,760
2026-03-04 MORRIS SHANNON R. M.D., PH.D. Officer — 20,000 $1.70 $34,000
2026-01-07 GARNER EBUN S General Counsel — 120,000 $5.59 $670,812
2026-01-07 GARNER EBUN S General Counsel — 120,000 $1.70 $204,000
2025-12-15 GARNER EBUN S General Counsel — 3,902 $3.43 $13,384
2025-05-23 MULTANI PRATIK S Director — 6,200 $0.00 $0
2024-05-21 CASDIN ALEXANDER W Director — 80,000 $2.27 $181,920
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
131.41
-16.35%
157.09
+11.00%
141.53
-2.70%
145.45
Research And Development
92.85
-19.51%
115.36
+11.11%
103.82
-7.68%
112.46
Selling General And Administration
38.55
-7.61%
41.73
+10.67%
37.70
+14.28%
32.99
General And Administrative Expense
38.55
-7.61%
41.73
+10.67%
37.70
+14.28%
32.99
Other Gand A
38.55
-7.61%
41.73
+10.67%
37.70
+14.28%
32.99
Total Expenses
131.41
-16.35%
157.09
+11.00%
141.53
-2.70%
145.45
Operating Income
-131.41
+16.35%
-157.09
-11.00%
-141.53
+2.70%
-145.45
Total Operating Income As Reported
-140.91
+21.54%
-179.59
-26.89%
-141.53
+42.81%
-247.45
EBITDA
-128.30
+16.30%
-153.28
-11.24%
-137.79
+3.51%
-142.81
Normalized EBITDA
-118.80
+9.16%
-130.78
+5.09%
-137.79
-237.65%
-40.81
Reconciled Depreciation
3.11
-18.34%
3.81
+1.96%
3.73
+41.31%
2.64
EBIT
-131.41
+16.35%
-157.09
-11.00%
-141.53
+2.70%
-145.45
Total Unusual Items
-9.50
+57.78%
-22.50
0.00
+100.00%
-102.00
Total Unusual Items Excluding Goodwill
-9.50
+57.78%
-22.50
0.00
+100.00%
-102.00
Special Income Charges
-9.50
+57.78%
-22.50
0.00
+100.00%
-102.00
Other Special Charges
9.50
-57.78%
22.50
—
102.00
Net Income
-124.55
+22.95%
-161.65
-29.28%
-125.04
+48.50%
-242.81
Pretax Income
-124.55
+22.95%
-161.65
-29.28%
-125.04
+48.50%
-242.81
Net Non Operating Interest Income Expense
16.61
-17.35%
20.09
+20.23%
16.71
+240.92%
4.90
Net Interest Income
16.61
-17.35%
20.09
+20.23%
16.71
+240.92%
4.90
Interest Income Non Operating
16.61
-17.35%
20.09
+20.23%
16.71
+240.92%
4.90
Interest Income
16.61
-17.35%
20.09
+20.23%
16.71
+240.92%
4.90
Other Income Expense
-9.75
+60.46%
-24.66
-10666.81%
-0.23
+99.78%
-102.26
Other Non Operating Income Expenses
-0.25
+88.50%
-2.16
-841.48%
-0.23
+10.89%
-0.26
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-124.55
+22.95%
-161.65
-29.28%
-125.04
+48.50%
-242.81
Net Income From Continuing Operation Net Minority Interest
-124.55
+22.95%
-161.65
-29.28%
-125.04
+48.50%
-242.81
Net Income From Continuing And Discontinued Operation
-124.55
+22.95%
-161.65
-29.28%
-125.04
+48.50%
-242.81
Net Income Continuous Operations
-124.55
+22.95%
-161.65
-29.28%
-125.04
+48.50%
-242.81
Normalized Income
-115.05
+17.32%
-139.15
-11.28%
-125.04
+11.19%
-140.81
Net Income Common Stockholders
-124.55
+22.95%
-161.65
-29.28%
-125.04
+48.50%
-242.81
Diluted EPS
—
-0.69
+16.87%
-0.83
+58.29%
-1.99
Basic EPS
—
-0.69
+16.87%
-0.83
+58.29%
-1.99
Basic Average Shares
—
233.82
+55.69%
150.18
+23.08%
122.02
Diluted Average Shares
—
233.82
+55.69%
150.18
+23.08%
122.02
Diluted NI Availto Com Stockholders
-124.55
+22.95%
-161.65
-29.28%
-125.04
+48.50%
-242.81
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
396.15
-21.17%
502.53
+27.13%
395.30
-23.23%
514.91
Current Assets
286.24
-7.30%
308.79
-3.71%
320.68
-27.86%
444.50
Cash Cash Equivalents And Short Term Investments
276.07
-7.45%
298.31
-4.50%
312.35
-28.30%
435.62
Cash And Cash Equivalents
73.81
+8.95%
67.74
-27.22%
93.08
-67.25%
284.22
Other Short Term Investments
202.27
-12.27%
230.57
+5.15%
219.28
+44.83%
151.40
Prepaid Assets
—
—
—
—
Other Current Assets
10.16
-3.05%
10.48
+25.92%
8.33
-6.20%
8.88
Total Non Current Assets
109.92
-43.26%
193.73
+159.62%
74.62
+5.98%
70.41
Net PPE
42.33
-12.79%
48.54
-19.35%
60.19
-7.73%
65.23
Gross PPE
54.99
-6.07%
58.55
-13.16%
67.42
-1.91%
68.73
Accumulated Depreciation
-12.66
-26.50%
-10.01
-38.40%
-7.23
-106.63%
-3.50
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
29.03
-9.90%
32.22
-14.90%
37.86
-6.33%
40.42
Machinery Furniture Equipment
5.22
-1.02%
5.28
-8.50%
5.77
+1.82%
5.66
Construction In Progress
—
—
—
0.00
Other Properties
4.43
-6.58%
4.74
-15.64%
5.62
+16.72%
4.82
Leases
16.31
+0.00%
16.31
-10.23%
18.17
+1.88%
17.84
Investments And Advances
65.72
-53.77%
142.16
+1374.42%
9.64
0.00
Other Non Current Assets
1.86
-38.58%
3.03
-36.76%
4.79
-7.51%
5.18
Total Liabilities Net Minority Interest
70.98
-10.18%
79.03
+0.53%
78.61
-23.72%
103.06
Current Liabilities
28.51
-9.19%
31.39
+20.03%
26.16
-46.28%
48.69
Payables And Accrued Expenses
11.37
-29.48%
16.12
+41.31%
11.41
-68.56%
36.30
Payables
0.98
+109.62%
0.47
-76.60%
2.00
-91.32%
23.05
Accounts Payable
0.98
+109.62%
0.47
-76.60%
2.00
-91.32%
23.05
Current Accrued Expenses
10.39
-33.63%
15.66
+66.37%
9.41
-28.98%
13.25
Pensionand Other Post Retirement Benefit Plans Current
12.07
+13.35%
10.65
+3.30%
10.31
+9.75%
9.39
Current Debt And Capital Lease Obligation
5.07
+9.68%
4.62
+16.35%
3.97
+204.21%
1.30
Current Capital Lease Obligation
5.07
+9.68%
4.62
+16.35%
3.97
+204.21%
1.30
Other Current Liabilities
—
—
0.46
-72.54%
1.69
Total Non Current Liabilities Net Minority Interest
42.47
-10.83%
47.63
-9.19%
52.45
-3.52%
54.37
Long Term Debt And Capital Lease Obligation
42.07
-10.99%
47.27
-8.90%
51.89
-3.54%
53.79
Long Term Capital Lease Obligation
42.07
-10.99%
47.27
-8.90%
51.89
-3.54%
53.79
Other Non Current Liabilities
0.40
+10.22%
0.36
-36.04%
0.57
-1.22%
0.57
Stockholders Equity
325.17
-23.22%
423.50
+33.73%
316.69
-23.11%
411.85
Common Stock Equity
325.17
-23.22%
423.50
+33.73%
316.69
-23.11%
411.85
Capital Stock
0.03
+0.00%
0.03
+86.67%
0.01
+0.00%
0.01
Common Stock
0.03
+0.00%
0.03
+86.67%
0.01
+0.00%
0.01
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
284.16
+0.33%
283.22
+86.99%
151.46
+1.43%
149.33
Ordinary Shares Number
284.16
+0.33%
283.22
+86.99%
151.46
+1.43%
149.33
Additional Paid In Capital
1,216.72
+2.18%
1,190.73
+29.06%
922.61
+3.22%
893.85
Retained Earnings
-892.21
-16.22%
-767.66
-26.67%
-606.01
-26.00%
-480.97
Gains Losses Not Affecting Retained Earnings
0.63
+55.06%
0.41
+425.97%
0.08
+107.40%
-1.04
Other Equity Adjustments
0.63
+55.06%
0.41
+425.97%
0.08
+107.40%
-1.04
Total Equity Gross Minority Interest
325.17
-23.22%
423.50
+33.73%
316.69
-23.11%
411.85
Total Capitalization
325.17
-23.22%
423.50
+33.73%
316.69
-23.11%
411.85
Working Capital
257.73
-7.09%
277.40
-5.81%
294.52
-25.59%
395.81
Invested Capital
325.17
-23.22%
423.50
+33.73%
316.69
-23.11%
411.85
Total Debt
47.14
-9.15%
51.89
-7.11%
55.86
+1.38%
55.10
Capital Lease Obligations
47.14
-9.15%
51.89
-7.11%
55.86
+1.38%
55.10
Net Tangible Assets
325.17
-23.22%
423.50
+33.73%
316.69
-23.11%
411.85
Tangible Book Value
325.17
-23.22%
423.50
+33.73%
316.69
-23.11%
411.85
Available For Sale Securities
65.72
-53.77%
142.16
+1374.42%
9.64
—
Investmentin Financial Assets
65.72
-53.77%
142.16
+1374.42%
9.64
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-95.45
+12.76%
-109.42
-8.10%
-101.22
+1.98%
-103.26
Cash Flow From Continuing Operating Activities
-95.45
+12.76%
-109.42
-8.10%
-101.22
+1.98%
-103.26
Net Income From Continuing Operations
-124.55
+22.95%
-161.65
-29.28%
-125.04
+48.50%
-242.81
Depreciation Amortization Depletion
3.11
-18.34%
3.81
+1.96%
3.73
+41.31%
2.64
Depreciation
—
—
—
—
Depreciation And Amortization
3.11
-18.34%
3.81
+1.96%
3.73
+41.31%
2.64
Other Non Cash Items
9.50
-57.78%
22.50
—
102.00
Stock Based Compensation
24.90
-7.69%
26.97
+2.83%
26.23
+30.44%
20.11
Asset Impairment Charge
0.00
-100.00%
6.81
0.00
—
Operating Gains Losses
—
—
—
—
Gain Loss On Investment Securities
—
—
—
—
Change In Working Capital
-3.33
-291.82%
1.74
+113.41%
0.81
-94.85%
15.79
Change In Prepaid Assets
1.79
+174.63%
-2.40
-355.27%
0.94
+126.00%
-3.61
Change In Payables And Accrued Expense
-3.25
-166.92%
4.86
+252.62%
-3.19
-155.97%
5.69
Change In Accrued Expense
-3.77
-158.91%
6.40
+377.97%
-2.30
-145.85%
5.02
Change In Payable
0.51
+133.49%
-1.53
-72.91%
-0.89
-231.07%
0.68
Change In Account Payable
0.51
+133.49%
-1.53
-72.91%
-0.89
-231.07%
0.68
Change In Other Working Capital
-1.86
-154.37%
-0.73
-123.91%
3.06
-77.66%
13.70
Investing Cash Flow
100.42
+164.12%
-156.62
-71.69%
-91.22
-28.33%
-71.08
Cash Flow From Continuing Investing Activities
100.42
+164.12%
-156.62
-71.69%
-91.22
-28.33%
-71.08
Net PPE Purchase And Sale
-0.13
-113.33%
-0.06
+96.62%
-1.77
+87.80%
-14.55
Purchase Of PPE
-0.13
-113.33%
-0.06
+96.62%
-1.77
+87.80%
-14.55
Capital Expenditure
-9.63
+57.32%
-22.56
-3.61%
-21.77
-31.56%
-16.55
Net Investment Purchase And Sale
110.05
+182.09%
-134.06
-93.04%
-69.44
-27.35%
-54.53
Purchase Of Investment
-150.97
+62.57%
-403.38
-28.31%
-314.39
-134.04%
-134.33
Sale Of Investment
261.03
-3.08%
269.32
+9.95%
244.94
+206.95%
79.80
Net Intangibles Purchase And Sale
-9.50
+57.78%
-22.50
-12.50%
-20.00
-900.00%
-2.00
Purchase Of Intangibles
-9.50
+57.78%
-22.50
-12.50%
-20.00
-900.00%
-2.00
Financing Cash Flow
1.10
-99.54%
240.70
+18486.64%
1.29
-98.68%
98.08
Cash Flow From Continuing Financing Activities
1.10
-99.54%
240.70
+18486.64%
1.29
-98.68%
98.08
Net Common Stock Issuance
0.00
-100.00%
239.06
0.00
-100.00%
95.25
Proceeds From Stock Option Exercised
1.10
-33.01%
1.64
+26.33%
1.29
-54.14%
2.82
Net Other Financing Charges
—
—
—
—
Changes In Cash
6.07
+123.94%
-25.34
+86.74%
-191.14
-150.61%
-76.27
Beginning Cash Position
68.15
-27.10%
93.48
-67.16%
284.62
-21.13%
360.89
End Cash Position
74.21
+8.90%
68.15
-27.10%
93.48
-67.16%
284.62
Free Cash Flow
-105.08
+20.38%
-131.98
-7.31%
-122.99
-2.65%
-119.81
Amortization Of Securities
-5.09
+46.96%
-9.59
-37.97%
-6.95
-599.30%
-0.99
Common Stock Issuance
0.00
-100.00%
239.06
0.00
-100.00%
95.25
Issuance Of Capital Stock
0.00
-100.00%
239.06
0.00
-100.00%
95.25
Net Preferred Stock Issuance
—
—
—
0.00
Preferred Stock Issuance
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category